GlassScriptPhysician profile
Kymberly Cullar
NPI 1255363800
$9,599.80
in general payments reported to CMS, 2019-2025
23 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,415 · 2022: $1,982 · 2023: $1,990 · 2024: $2,565 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,661 · Travel and Lodging: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,660.94 |
| Travel and Lodging | $542.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,162.99 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,762.53 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,462.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,052.74 | 2022-2025 | Spravato |
| Neurocrine Biosciences, INC. | $490.15 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $454.11 | 2021-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $376.36 | 2021-2022 | |
| Corium, LLC | $316.04 | 2023-2025 | Azstarys |
| Lundbeck LLC | $209.84 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $202.07 | 2022-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $177.92 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $157.87 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $143.59 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $111.65 | 2025 | Cobenfy |
| Integra Lifesciences Corporation | $101.26 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $95.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $92.80 | 2021-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $69.03 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $51.11 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $39.58 | 2024 | |
| Tris Pharma INC | $30.17 | 2025 | Onyda Xr |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.00 | 2023 | Aplenzin |
| Vanda Pharmaceuticals INC. | $14.07 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kymberly Cullar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.